(Q42660595)

4 November 2017

Postmarketing experience with topiramate and cognition (English)

1 reference

4 November 2017

2

1 reference

4 November 2017

W O Tatum

1

1 reference

4 November 2017

E Faught

3

1 reference

4 November 2017

G L Morris

4

1 reference

4 November 2017

J Liporace

5

1 reference

4 November 2017

A Kanner

6

1 reference

4 November 2017

S L Goff

7

1 reference

4 November 2017

L Winters

8

1 reference

4 November 2017

A Fix

9

1 reference

4 November 2017

PADS Investigators. Post-marketing antiepileptic drug survey

10

1 reference

4 November 2017

1 September 2001

1 reference

4 November 2017

1 reference

4 November 2017

42

1 reference

4 November 2017

9

1 reference

4 November 2017

1134-1140

1 reference

Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs

4 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

Topiramate: a review of preclinical, pharmacokinetic, and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

Evaluation of case reports of aplastic anemia among patients treated with felbamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

Topiramate: a new antiepileptic drug for refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

Topiramate monotherapy for partial onset seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

Safety of topiramate: adverse events and relationships to dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.2001.41700.X

10.1046/J.1528-1157.2001.41700.X

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference